Fintel reports that on September 16, 2026, Needham upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) from Hold to Buy.
Rocket Pharmaceuticals, Inc., headquartered in the United States, is at the forefront of the biotechnological industry, specializing in the development of gene therapies. The company is primarily engaged in pioneering advanced treatments for rare and devastating genetic diseases. Among its key projects are gene therapy platforms targeting disorders like Fanconi anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. These therapeutic platforms employ cutting-edge technologies including lentiviral and adeno-associated viral vectors, representing transformative advances in gene therapy aimed at correcting severe genetic disorders at their root cause. Rocket Pharmaceuticals is committed to rigorous clinical trials and scientific research to ensure the efficacy and safety of its therapies, aiming to provide long-term solutions for conditions with limited treatment options.
On September 16, 2026, the latest close for Rocket Pharmaceuticals was $3.49, following a pre-action close of $3.41 on September 15, 2026. The stock has seen a price change of -3.86% over one week, relative to a baseline close of $3.63 on September 9, 2026. Over a one-month period, the price change was +0.58%, compared to a baseline close of $3.47 on August 14, 2026.
Separate from Needham's individual rating, the current consensus target mean for the stock is $9.02 as of September 16, 2026, representing an implied change of +158.39% from recent levels. The current consensus target median is $10.20. This current mean target represents a revision of +2.50% from the prior consensus target mean of $8.80 recorded on August 28, 2026.
Rocket Pharmaceuticals reported its latest earnings on August 10, 2026. The actual earnings per share (EPS) was -0.48, compared to an estimated EPS of 0.2467, representing an EPS surprise percent of -294.57%. The actual revenue for the period was $0.00, while the estimated revenue was $20,400,000.00.
On the same day as Needham's action, September 16, 2026, Wedbush reiterated its Outperform rating on the stock. Other recent rating actions include Chardan Capital maintaining its Buy rating on September 15, 2026, and previously maintaining its Buy rating on September 1, 2026.
As of the current recommendation period starting September 1, 2026, the aggregate recommendation breakdown consists of 4 strong buy, 7 buy, 7 hold, 2 sell, and 0 strong sell recommendations, totaling 20 recommendations. This breakdown reflects 55.0% positive, 35.0% hold, and 10.0% negative recommendations. This distribution is unchanged from the prior recommendation period starting August 1, 2026, which also had 4 strong buy, 7 buy, 7 hold, 2 sell, and 0 strong sell recommendations.
Recent analyst actions
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
